Trial Profile

A 6-week, Randomised, Multi-centre, Open-labelled, Parallel Group, Exploratory Trial to Investigate the Safety of SIAC Compared to Mix30 (NovoRapid 30Mix) on a Twice Daily Regimen in Subjects With Type 2 Diabetes Mellitus

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 11 Feb 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Insulin aspart/insulin protamine aspart (Primary) ; Insulin degludec/insulin aspart (Primary)
Indications Type 2 diabetes mellitus
Focus Adverse reactions
Sponsors Novo Nordisk

03 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
03 Jul 2009 Actual patient number (65) added as reported by ClinicalTrials.gov.
08 Apr 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com